Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of MNK-1411 in boys aged 4 to 8 years with Duchenne muscular dystrophy
MOH_2018-09-13_003655Phase 2Completed
- Sponsor
- Mallinckrodt ARD
- Start
- Apr 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MNK-1411 in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Mallinckrodt ARD. Started Apr 2018; status: completed.
02
Drugs
MNK-1411
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2018-09-13_003655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-09-13_003655.